Efficacy of Aprepitant in Prevention of Vomiting During Multiple Cycles of Cisplatin-based Chemotherapy in Lung Cancer

Abstract

Abstract: Objective To analyze the efficacy of aprepitant in the prevention of vomiting during multiple cycles of cisplatin-based chemotherapy in lung cancer. Methods 95 cases of patients with lung cancers who received four or six cycles of cisplatin-based chemotherapy were selected retrospectively. All the patients received antiemetic regimen including aprepitant: aprepitant (125 mg po D1, 80 mg po D2~D3), ondansetron (8 mg iv bid D1~D3) and dexamethasone (5 mg iv D1-D3). The complete response rate of vomitting, nausea-free rate and adverse effect were observed. Results 24 and 73 patients received 4 and 6 cycles of cisplatin-based chemotherapy respectively. Complete response rates ranged from 71.2% to 78.9% with no significant decline during continuous cycles of chemotherapy. 61.1% to 68.4% of patients were nausea-free during chemotherapy. The reported side effects were mild fatigue, constipation, hiccup, diarrhea and insomnia. Conclusion The combination of aprepitant, ondansetron and dexamethasone enhanced the antiemetic protection, and its efficacy was also sustained for up to six cycles of cisplatin-based chemotherapy in lung cancer patients.

Key words: aprepitant, lung cancer, cisplatin, multiple cycles of chemotherapy, nausea and vomiting

CLC Number:

R975.4

BIE Zhi-xin, ZHANG Shuai, LI Xu, ZHANG Zi-jin, AI Bin, CHENG Gang. Efficacy of Aprepitant in Prevention of Vomiting During Multiple Cycles of Cisplatin-based Chemotherapy in Lung Cancer[J]. Chinese Journal of Pharmacovigilance, 2018, 15(6): 329-332.

References

[1] 李爱洁, 陶海涛, 汪进良, 等.阿瑞匹坦预防顺铂化疗所致恶心和呕吐的疗效分析[J]. 中国药物应用与监测, 2015,(2):73-75,81.
[2] Aapro M, Carides A, Rapoport B L, et al.Aprepitant and fosaprepitant: a 10-year review of efficacy and safety[J]. Oncologist, 2015,20(4):450-458.
[3] Longo F, Mansueto G, Lapadula V, et al.Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy[J]. Int J Clin Pract, 2012,66(8):753-757.
[4] Ettinger D S, Wood D E, Aisner D L, et al.Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2017,15(4):504-535.
[5] Storz E, Gschwend J E, Retz M.Chemotherapy-induced nausea and vomiting:Current recommendations for prophylaxis[J]. Urologe A, 2018,57(5):532-542.
[6] 于世英, 印季良, 秦叔逵, 等. 肿瘤治疗相关呕吐防治指南(2014版)[J]. 临床肿瘤学杂志, 2014,(3):263-273.
[7] de Wit R, van den Berg H, Burghouts J, et al. Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles[J]. Br J Cancer, 1998,77(9):1487-1491.
[8] Hu Z, Cheng Y, Zhang H, et al.Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial[J]. Support Care Cancer, 2014,22(4):979-987.
[9] 陈丽昆, 程颖, 张红雨, 等. 阿瑞吡坦在中国肺癌患者中预防高剂量顺铂引起恶心和呕吐的疗效(英文)[J]. 中国新药与临床杂志, 2015,(10):757-763.
[10] Suzuki S, Karayama M, Inui N, et al.Sequential addition of aprepitant in patients receiving carboplatin-based chemotherapy[J]. Med Oncol, 2016,33(7):65.
[11] de Wit R, Herrstedt J, Rapoport B, et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy[J]. J Clin Oncol, 2003,21(22):4105-4111.
[12] Gralla R J, Bosnjak S M, Hontsa A, et al.A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy[J]. Ann Oncol, 2014,25(7):1333-1339.
[13] 毛丽丽, 斯璐, 王轩, 等. 阿瑞匹坦对黑色素瘤患者顺铂治疗引起恶心呕吐的止吐作用[J]. 肿瘤防治研究, 2015,(7):712-715.
[14] dos SLV, Souza FH, Brunetto AT, et al. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review[J]. J Natl Cancer Inst, 2012,104(17):1280-1292.
[15] Dushenkov A, Kalabalik J, Carbone A, et al.Drug interactions with aprepitant or fosaprepitant: Review of literature and implications for clinical practice[J]. J Oncol Pharm Pract, 2016,23(4):296-308.